Nuveen Asset Management, LLC Humanigen, Inc Transaction History

Nuveen Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.76 - $3.33 $867,562 - $1.64 Million	-492,933 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.81 - $3.97 $197,568 - $433,341	-109,154 Reduced 18.13%	492,933 $1.78 Million
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $1.52 Million - $3.41 Million	415,262 Added 222.27%	602,087 $2.24 Million
Q3 2021 Nov 12, 2021	BUY	$5.93 - $17.83 $185,858 - $558,827	31,342 Added 20.16%	186,825 $1.11 Million
Q2 2021 Aug 16, 2021	BUY	$13.54 - $22.74 $2.11 Million - $3.54 Million	155,483 New	155,483 $2.7 Million

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.